Paper Details

  1. Home
  2. Paper Details

CYP2D6 genotype- and endoxifen-guided tamoxifen dose escalation increases endoxifen serum concentrations without increasing side effects.

Author: DezentjéV O, DieudonnéA S, GelderblomH, GuchelaarH-J, Hartigh denJ, MaartenseE, NevenP, NortierJ W R, OpdamF L, PutterH, SmorenburgC H, Van de VeldeC J H, Van der StraatenT, VreeR

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.

Overview

Breast cancer patients with absent or reduced CYP2D6 activity may have lower endoxifen levels and less benefit from tamoxifen treatment. This study found that a one-step tamoxifen dose escalation significantly increased endoxifen concentrations in CYP2D6 poor and intermediate metabolizers, without increasing side effects. Further research is needed to assess long-term safety and effectiveness.
Paper Details　
Original Abstract of the Article :
Breast cancer patients with absent or reduced CYP2D6 activity and consequently low endoxifen levels may benefit less from tamoxifen treatment. CYP2D6 poor and intermediate metabolizers may need a personalized increased tamoxifen dose to achieve effective endoxifen serum concentrations, without incre...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4589558/

データ提供：米国国立医学図書館（NLM）

A Personalized Journey: Tailoring Tamoxifen Treatment for Breast Cancer

Imagine a caravan traversing a vast desert, each camel requiring unique provisions and adjustments for a safe and successful journey. This research explores the potential of personalized tamoxifen treatment for breast cancer patients, tailoring the dosage based on individual CYP2D6 genotype and endoxifen levels. This study aims to determine if dose escalation can effectively increase endoxifen levels without increasing the risk of side effects. This is like ensuring each camel has the right amount of water and supplies to thrive in the desert.

The researchers found that dose escalation significantly increased endoxifen concentrations in patients with absent or reduced CYP2D6 activity. This is like providing additional water and supplies to camels that are struggling to keep up, ensuring their well-being and allowing them to continue their journey successfully.

A More Effective Journey: Personalized Tamoxifen Treatment

The study's findings suggest that personalized tamoxifen treatment based on CYP2D6 genotype and endoxifen levels may be a more effective approach for breast cancer patients. This is like ensuring each camel in the caravan has the resources they need to thrive in the desert, leading to a more successful and fulfilling journey.

Navigating the Desert of Breast Cancer: Implications for Patients

This research provides valuable information for breast cancer patients. It suggests that personalized tamoxifen treatment may be a more effective and safer approach. Patients should discuss the potential benefits and risks of personalized treatment with their doctors to make informed decisions about their care.

Dr.Camel's Conclusion

This research sheds light on the importance of personalized treatment for breast cancer. Tailoring tamoxifen dosage based on CYP2D6 genotype and endoxifen levels has the potential to enhance treatment efficacy and safety for patients. This study highlights the crucial role of personalized medicine in navigating the complex landscape of breast cancer treatment.

Date :
  1. Date Completed 2016-07-11
  2. Date Revised 2018-11-13
Further Info :

Pubmed ID

26369533

DOI: Digital Object Identifier

PMC4589558

Related Literature

Article Analysis
・Side Effects of tamoxifen
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.